All In Biotech

Investigational drug · Phase 2

PF-0704091

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer.

Phase 2

Last checked: Nov 19, 2026Latest source record: May 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "PF-0704091"

First trial start

2020

Sep 16, 2020

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "PF-0704091", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Small Cell Lung Cancer
  • Ovarian Cancer
  • Breast Cancer

Approved drugs for the same conditions: Breast cancer · Small cell lung cancer · Ovarian cancer · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "PF-0704091" as an intervention, largest first.

All trials
  • PfizerPfizer (PFE)

    NCT04553133 · 157 participants · Start Sep 16, 2020 · Primary completion Dec 31, 2026

    Drug: PF-07104091 monotherapy dose escalation; PF-07104091 + palbociclib + fulvestrant and 5 more · For: Small Cell Lung Cancer; Ovarian Cancer; Breast Cancer

    Sites: Clive, Iowa; Des Moines, Iowa; Louisville, Kentucky · 22 sites in all

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Small Cell Lung Cancer

  • BMS-986507BL-B01D1, Iza-brenPhase 351 trials

    Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma

  • IvonescimabAK112, SMT112Phase 349 trials

    Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors

  • I-DXdDS-7300a, MK-2400Phase 317 trials

    Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma

  • SYS6010Phase 315 trials

    CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma

  • YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials

    MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer

  • ZG005Phase 311 trials

    Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer

  • ZG006Phase 38 trials

    Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Neuroendocrine Carcinoma, Small Cell Lung Cancer, Solid Tumor

  • ObrixtamigBI 764532Phase 36 trials

    Boehringer Ingelheim · Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Pfizer.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.